What next after GDP-based cost-effectiveness thresholds?
Open Access
- 30 November 2020
- journal article
- research article
- Published by F1000 Research Ltd in Gates Open Research
- Vol. 4, 176
Abstract
Public payers around the world are increasingly using cost-effectiveness thresholds (CETs) to assess the value-for-money of an intervention and make coverage decisions. However, there is still much confusion about the meaning and uses of the CET, how it should be calculated, and what constitutes an adequate evidence base for its formulation. One widely referenced and used threshold in the last decade has been the 1-3 GDP per capita, which is often attributed to the Commission on Macroeconomics and WHO guidelines on Choosing Interventions that are Cost Effective (WHO-CHOICE). For many reasons, however, this threshold has been widely criticised; which has led experts across the world, including the WHO, to discourage its use. This has left a vacuum for policy-makers and technical staff at a time when countries are wanting to move towards Universal Health Coverage. This article seeks to address this gap by offering five practical options for decision-makers in low- and middle-income countries that can be used instead of the 1-3 GDP rule, to combine existing evidence with fair decision-rules or develop locally relevant CETs. It builds on existing literature as well as an engagement with a group of experts and decision-makers working in low, middle and high income countries.Keywords
Funding Information
- Rockefeller Foundation
- Bill and Melinda Gates Foundation (INV-006987)
- South African Medical Research Council (23108)
This publication has 55 references indexed in Scilit:
- Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of VaccinesPharmacoEconomics, 2014
- The use of economic evaluation for guiding the pharmaceutical reimbursement list in ThailandZeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2014
- Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task ForceValue in Health, 2014
- Applying rapid ‘de-facto’ HTA in resource-limited settings: Experience from RomaniaHealth Policy, 2013
- Using health technology assessment for informing coverage decisions in ThailandJournal of Comparative Effectiveness Research, 2012
- Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force ReportValue in Health, 2009
- Government health expenditures and health outcomesHealth Economics, 2006
- Cost-Effectiveness League TablesPharmacoEconomics, 2003
- Oregon's Medicaid Ranking and Cost- EffectivenessMedical Decision Making, 1996
- Cost-effectiveness league tables: More harm than good?Social Science & Medicine, 1993